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In a recent issue of Critical Care, Dr King and colleagues [1]
described the role of cardiac troponin as a prognosticator in
critically ill medical patients. They concluded that elevated
troponin levels measured on admission are associated with
an increased mortality rate.
Our experience [2] supports that reported by King and
coworkers. Our retrospective case note study, conducted in
180 consecutive admissions to our general (noncardio-
thoracic) intensive care unit over a 5-month period, identified
62 patients with a raised troponin T (TnT) level. The all-cause
mortality rate was 51.6% in those patients with a raised TnT,
as compared with 20.3% in patients with no TnT elevation
(P < 0.001). The median duration of admission was 5.5 days
for patients with a raised TnT and 3 days for patients with a
normal TnT (P < 0.003). In over 70% of cases the raised TnT
occurred within the first 72 hours of admission.
Other groups have also reported that elevated biochemical
markers of cardiac myocyte damage are common in critically
ill patients and are associated with increased mortality [3].
TnT and troponin I are sensitive and specific for myocardial
injury, even at the microscopic level. Although the cardiac
troponins are cardiospecific, in many critically ill patients an
elevated troponin level will not reflect myocardial ischaemia
secondary to obstructive coronary artery disease, as in the
setting of acute coronary syndrome (ACS) [3]. In one study
[4] 55% of critically ill patients with raised troponins fulfilled
criteria for myocardial infarction, and this group had the worst
outcome. It is likely, but not proven, that in those patients
without myocardial infarction cardiac troponin level
represents another surrogate marker of disease severity.
In spite of the different trigger for troponin release in this
latter group (i.e. commonly sepsis in critically ill patients
versus atheromatous coronary plaque in the ACS population),
there may be similarities between the pathophysiology of
ACS and that of myocardial dysfunction in the critically ill.
Research in ACS patients has revealed complex associations
between cardiac biomarkers and outcome, reflecting the
different pathophysiological axes that are involved in the ACS
setting. The simultaneous measurement of three biomarkers
provides independent prognostic information [5]. Troponin is a
marker of myocardial necrosis, high sensitivity C-reactive
protein is a marker of inflammation, and B-type natriuretic
peptide is part of the neurohormonal axis and reflects
ventricular loading. The number of elevated biomarkers allows
patients to be risk stratified for short-term (30 days) and long-
term (>6 months) adverse events, including death, myocardial
infarction and congestive cardiac failure, with a fivefold range of
risk identified. Also, with each additional elevated biomarker,
the risk for death is almost doubled.
Further research is required to unravel the complex
pathophysiology that leads to troponin release in the critically
ill. However, we believe that it is likely that troponin release
forms one part of a much larger puzzle.
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